Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Di | Day One Biopharmaceuticals, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
06.05. | Day One Biopharmaceuticals, Inc.: Day One Reports First Quarter 2025 Financial Results and Corporate Progress | 237 | GlobeNewswire (Europe) | OJEMDA (tovorafenib) prescriptions grew 16% in Q1 2025 compared to Q4 2024 Achieved Q1 2025 OJEMDA (tovorafenib) net product revenue of $30.5 million Ended the first quarter with $473.0 million in... ► Artikel lesen | |
06.05. | Day One Biopharmaceuticals, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
06.05. | Day One Biopharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
22.04. | Day One Biopharmaceuticals, Inc.: Day One to Report First Quarter 2025 Financial Results Tuesday, May 6, 2025 | 6 | GlobeNewswire (USA) | ||
03.04. | H.C. Wainwright maintains Buy on Day One Biopharmaceuticals | 8 | Investing.com | ||
06.03. | Day One Biopharmaceuticals, Inc. - 10-K/A, Annual Report | 1 | SEC Filings | ||
DAY ONE BIOPHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
26.02. | Day One Biopharmaceuticals stock target cut to $36 at H.C. Wainwright | 8 | Investing.com | ||
25.02. | Day One Biopharmaceuticals GAAP EPS of -$1.02 misses by $0.29, revenue of $131.16M beats by $8.64M | 2 | Seeking Alpha | ||
25.02. | Day One Biopharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
11.02. | Day One Biopharmaceuticals, Inc.: Day One to Report Fourth Quarter and Full-Year 2024 Financial Results Tuesday, February 25, 2025 | 7 | GlobeNewswire (USA) | ||
23.01. | Why Is Andreas Halvorsen Bullish On Day One Biopharmaceuticals, Inc. (DAWN) Now? | 13 | Insider Monkey | ||
13.01. | Day One Biopharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
10.01. | Day One Biopharmaceuticals, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
30.10.24 | Day One Biopharmaceuticals, Inc.: Day One Reports Third Quarter 2024 Financial Results and Corporate Progress | 370 | GlobeNewswire (Europe) | Achieved $20.1 million in OJEMDATM (tovorafenib) net product revenue Ended the third quarter with $558.4 million in cash, cash equivalents and short-term investments Company to host conference call... ► Artikel lesen | |
30.07.24 | Day One Biopharmaceuticals, Inc.: Day One Reports Second Quarter 2024 Financial Results and Corporate Progress | 349 | GlobeNewswire (Europe) | Achieved $8.2 million in OJEMDATM (tovorafenib) net product revenues in initial 2 months of launch Expanded pipeline with DAY301, potential first-in-class Antibody Drug Conjugate (ADC) targeting... ► Artikel lesen | |
18.06.24 | Day One Biopharmaceuticals, Inc.: Day One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting PTK7 in Solid Tumors for Adult and Pediatric Cancers | 378 | GlobeNewswire (Europe) | Day One receives exclusive license for development and commercialization of MTX-13 (DAY301), which received IND clearance by the FDA in April 2024 Targets PTK7, highly expressed in broad range of... ► Artikel lesen | |
12.06.24 | XOMA Corporation: XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals' Sale of its Priority Review Voucher | 371 | GlobeNewswire (Europe) | EMERYVILLE, Calif., June 12, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today it has received an $8.1 million milestone payment from Viracta... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 95,35 | +0,05 % | Summit Therapeutics crasht - BioNTech in Sippenhaft | Wie gewonnen, so zerronnen: Die Aktie von Summit Therapeutics brach am vergangenen Freitag an der Nasdaq um rund 30 Prozent ein. Weitere Studiendaten zum großen Hoffnungsträger Ivonescimab, den die... ► Artikel lesen | |
CUREVAC | 3,830 | -0,83 % | Kauf-Alarm bei CureVac: Insider decken sich massenhaft mit Aktien ein - Das müssen Sie jetzt beachten! | ||
AMGEN | 254,90 | +0,08 % | Amgen Says Imdelltra Cut Risk Of Death By 40% In Small Cell Lung Cancer Patients | THOUSAND OAKS (dpa-AFX) - Amgen Inc. (AMGN) Monday announced positive interim results from the Phase 3 DeLLphi-304 study showing Imdelltra reduced the risk of death by 40% and significantly... ► Artikel lesen | |
NOVAVAX | 6,520 | -0,20 % | Aktien New York: Rücksetzer nach US-Bonitätsabstufung verpufft | NEW YORK (dpa-AFX) - Die Abstufung der US-Kreditwürdigkeit durch Moody?s hat die Anleger in New York am Montag nicht lange beeindruckt. Benoit Anne, Anleiheexperte bei MFS Investment Management, verwies... ► Artikel lesen | |
BIOGEN | 116,70 | -0,09 % | DAX tritt auf der Stelle - Nvidia & Biogen mit Überraschung! Gold, EUR & Aktien im Chartcheck | ||
CRISPR THERAPEUTICS | 36,800 | 0,00 % | AKTIONÄR-Depotwert CRISPR Therapeutics: Cathie Wood kauft erneut | Die Aktie des Gen-Schere-Spezialisten CRISPR Therapeutics kommt seit Monaten nicht von der Stelle. Das aktuelle Niveau hat nun aber Cathie Wood zum Kauf genutzt. Die für Donnerstag veröffentlichten... ► Artikel lesen | |
MAINZ BIOMED | 2,775 | -100,00 % | MAINZ BIOMED N.V. - 6-K, Report of foreign issuer | ||
VIKING THERAPEUTICS | 24,220 | -0,78 % | Viking Therapeutics auf Jefferies-Konferenz: Vielversprechendes Abnehm-Medikament | ||
INTELLIA THERAPEUTICS | 7,146 | +0,37 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | CAMBRIDGE, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies... ► Artikel lesen | |
BIOCRYST PHARMACEUTICALS | 9,668 | -0,17 % | BioCryst Pharmaceuticals, Inc.: BioCryst Achieves Reimbursement for ORLADEYO Across all Major European Countries | RESEARCH TRIANGLE PARK, N.C., June 06, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that, following a positive recommendation from the Zorginstituut Nederland... ► Artikel lesen | |
TEMPUS AI | 54,74 | +0,51 % | Opening Bell: Constellation Energy, Vistra, Netflix, Applied Digital, Steel Dyn., Pony.ai, Tempus AI | Zum Wochenauftakt schwankten die US-Börsen zwischen neuen Zolldrohungen und der Hoffnung auf sinkende Zinsen. Zwar sorgte US-Präsident Trumps verschärfte Rhetorik im Handelsstreit mit China zunächst... ► Artikel lesen | |
SAREPTA THERAPEUTICS | 38,180 | +1,17 % | FDA Grants Platform Technology Status To Sarepta's RAAVrh74 Vector | WASHINGTON (dpa-AFX) - Sarepta Therapeutics (SRPT), Wednesday announced that the FDA has designated its rAAVrh74 viral vector used in the investigational gene therapy SRP-9003 for limb-girdle... ► Artikel lesen | |
CARDIOL THERAPEUTICS | 1,218 | -1,30 % | H.C. Wainwright initiates Cardiol Therapeutics stock with buy rating | ||
PACIFIC BIOSCIENCES OF CALIFORNIA | 1,000 | +1,26 % | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. - 8-K, Current Report | ||
EXELIXIS | 37,400 | -0,93 % | BofA Hikes Exelixis, Inc. (EXEL) Target Amid CRC Caution |